Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.

Antimicrobial Agents and Chemotherapy
P PatamasuconJ D Nelson

Abstract

We studied the pharmacokinetics of erythromycin estolate and ethylsuccinate suspensions in infants under 4 months of age who were being treated for chlamydial infections or pertussis. We conducted our studies after the initial dose of 10 mg/kg and subsequently during steady-state treatment. The estolate preparation resulted in higher peak concentrations in sera, and its absorption and elimination half-lives were longer. Peak concentrations occurred 3 h after a dose with the estolate preparation and 1 h after a dose with the ethylsuccinate preparation. The area under the curve for the estolate preparation was about three times greater than that for the ethylsuccinate preparation. Based on these findings, we recommend that erythromycin estolate suspensions be given to young infants at 8- or 12-h intervals (30 mg/kg per day in three divided doses or 20 mg/kg per day in two divided doses) and that erythromycin ethylsuccinate is best given at 6-h intervals (40 mg/kg per day in four divided doses).

References

Dec 1, 1976·The Journal of Pediatrics·C M Ginsburg, H F Eichenwald
Apr 1, 1970·Applied Microbiology·H J Simon, E J Yin
Aug 1, 1969·Applied Microbiology·P L TardrewD Kenney
Jan 1, 1957·Antibiotica Et Chemotherapia. Fortschritte. Advances. Progrès·J O FORFAR, A F MACCABE
Sep 1, 1963·American Journal of Diseases of Children·L BURNS, J HODGMAN

❮ Previous
Next ❯

Citations

Dec 31, 1997·The Pediatric Infectious Disease Journal·M D Reed, J L Blumer
Oct 15, 2005·Clinical Microbiology Reviews·Ken B WaitesRobert L Schelonka
Mar 23, 2011·Drug Metabolism and Drug Interactions·Iftekhar Mahmood
Jan 1, 1988·Scandinavian Journal of Infectious Diseases·I Sandström, O Ringertz
Oct 17, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Manfred Hauben, Guy W Amsden
Aug 30, 2008·Drug Discovery Today·Saskia N de WildtGideon Koren
Nov 1, 1983·American Journal of Otolaryngology·J D Nelson
Nov 13, 2008·Journal of Veterinary Pharmacology and Therapeutics·G A AlbarellosM Rebuelto
Jun 2, 2006·The Journal of Pediatrics·Pracha NuntnarumitSuppawat Boonkasidecha
Feb 21, 2007·Journal of Chemotherapy·V FanosM Testa
Mar 29, 2002·Clinics in Perinatology·Laura P James

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.